We are live on ! Find out more
BB

BB Biotech Portfolio holdings

AUM $3.98B
1-Year Est. Return 15.47%
This Fund
S&P 500
This Quarter Est. Return
+3.08%
1 Year Est. Return
+15.47%
3 Year Est. Return
+121.5%
5 Year Est. Return
+265.65%
10 Year Est. Return
–
AUM
$3.55B
AUM Growth
-$61.4M
Cap. Flow
+$136M
Cap. Flow %
3.83%
Top 10 Hldgs %
70.18%
Holding
30
New
3
Increased
10
Reduced
6
Closed
–
Avg Time Held
11.4 quarters
Top 10 Avg Time Held
12.4 quarters
Top 20 Avg Time Held
12.2 quarters

Top Buys

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$27.1M
2
VYGR icon
Voyager Therapeutics
VYGR
+$26.4M
3
WVE icon
Wave Life Sciences
WVE
+$25M
4
AKCA
Akcea Therapeutics Inc
AKCA
+$24.5M
5
IONS icon
Ionis Pharmaceuticals
IONS
+$15M

Top Sells

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$7.54M
2
JUNO
Juno Therapeutics, Inc.
JUNO
+$6.48M
3
SAGE icon
Sage Therapeutics
SAGE
+$4.85M
4
HALO icon
Halozyme
HALO
+$1.95M
5
AGIO icon
Agios Pharmaceuticals
AGIO
+$1.89M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
FPRX
26
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$18.1M 0.51%
827,500
+50,000
+6% +$1.61M
2017 Q1
3 quarters
CDTX icon
27
DELISTED
Cidara Therapeutics
CDTX
$15.6M 0.44%
114,764
+48,000
+72% +$7.28M
2015 Q4
8 quarters
PRTA icon
28
Prothena Corp
PRTA
$436M
$13.1M 0.37%
350,000
– –
2015 Q3
9 quarters
NVAX icon
29
Novavax
NVAX
$2.07B
$10.3M 0.29%
416,500
– –
2014 Q3
13 quarters
ACHN
30
DELISTED
Achillion Pharmaceuticals
ACHN
$3.68M 0.1%
1,279,340
– –
2013 Q2
18 quarters
1
2

Similar funds

SBAM
Santa Barbara Asset Management Los Angeles, California $6.43B AUM 10.99% 1-Year Est. Return
HFS
HL Financial Services Louisville, Kentucky $6.5B AUM 9.56% 1-Year Est. Return
SA
SQ Advisors Naples, Florida $1.32B AUM 10.3% 1-Year Est. Return
WF
WealthTrust Fairport Cleveland, Ohio $1.06B AUM 3.47% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
AB
AT Bancorp Dubuque, Iowa $823M AUM 0.35% 1-Year Est. Return
MFBTD
MB Financial Bank - Trust Department Rosemont, Illinois $816M AUM 5.49% 1-Year Est. Return

BB Biotech's Q4 2017 Portfolio in Review

As of Q4 2017, BB Biotech held 30 positions worth $3.55B, down 1.7% from $3.61B the previous quarter. Its ten largest holdings account for 70% of the portfolio.

BB Biotech deployed $136M of net new capital in Q4 2017, opening 3 new positions and adding to 10 existing holdings. Its largest new stake was Voyager Therapeutics: 1,539,520 shares worth $25.6M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Alnylam Pharmaceuticals, an estimated $7.54M trimmed.

  • BB Biotech's largest Q4 2017 buy was Voyager Therapeutics: 1,539,520 shares worth $25.6M.
  • BB Biotech added most to Celgene Corp in Q4 2017, an estimated $27.1M increase.
  • BB Biotech's biggest Q4 2017 reduction was Alnylam Pharmaceuticals, cutting an estimated $7.54M.
  • BB Biotech's ten largest holdings make up 70% of its $3.55B portfolio in Q4 2017.
  • BB Biotech opened 3 new positions and closed 0 in Q4 2017.
  • BB Biotech's portfolio value fell 1.7% quarter-over-quarter to $3.55B.

Based on BB Biotech's 13F filing for Q4 2017, filed 14 Feb 2018.